Authors : Madhab Mondal; Prerna Rai; Akash Baglari; Divyadarshi Rai; Pratiksha Chhetri; Purandar Sarkar

Volume/Issue : Volume 10 - 2025, Issue 9 - September

Google Scholar : https://tinyurl.com/yw8ncrjk

Scribd : https://tinyurl.com/565h88z5

DOI : https://doi.org/10.38124/ijisrt/25sep352

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Prostate cancer (PCa) progression is primarily driven by androgen receptor (AR) signaling, which orchestrates tumor proliferation and metabolic reprogramming. Alpha-Methyl Acyl-CoA Racemase (AMACR) is a key enzyme in branched-chain fatty acid β-oxidation which is widely recognized as a diagnostic marker for PCa but its regulatory association with AR and functional implications remain unclear. Using globally available multi-omics datasets, we analyzed RNA-seq profiles from TCGA-PRAD which revealed significant overexpression of AMACR in tumors compared to normal tissues (p < 0.001). Elevated AMACR levels correlated with advanced Gleason scores, nodal positivity, and poor overall survival (p = 0.027). Functional insights from androgen stimulation and antagonism datasets, along with Chipset analyses, demonstrated direct AR occupancy at enhasssncer regions near AMACR which further confirms androgen-dependent transcriptional regulation. Protein-level evidence from immunohistochemistry and immunofluorescence supported these findings. Collectively, these results establish AMACR as an AR-regulated biomarker in PCa, implicating it in metabolic dysregulation and disease aggressiveness, and highlight its potential as a therapeutic target within the androgen-driven oncogenic network.

Keywords : Prostate cancer, AMACR, Androgen receptor, Biomarker.

References :

1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019; 10: 63–89.
2. Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells 2020; 9: 2653.
3. Huang Y, Jiang X, Liang X, et al. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett 2018; 15: 6063–6076.
4. Li W, Cagle PT, Botero RC, et al. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res CR 2008; 27: 2.
5. Lloyd MD, Yevglevskis M, Lee GL, et al. α-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res 2013; 52: 220–230.
6. Jensen MA, Ferretti V, Grossman RL, et al. The NCI Genomic Data Commons as an engine for precision medicine. Blood 2017; 130: 453–459.
7. Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 2022; 25: 18–27.
8. McHugh ML. Multiple comparison analysis testing in ANOVA. Biochem Medica 2011; 21: 203–209.
9. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010; 1: 274–278.
10. Wang T, Alavian MR, Goel HL, et al. Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation. The Prostate 2008; 68: 1734–1742.
11. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. Nat Biotechnol 2011; 29: 24–26.
12. Thul PJ, Lindskog C. The human protein atlas: A spatial map of the human proteome. Protein Sci Publ Protein Soc 2018; 27: 233–244.